Releve Therapeutics owns a proprietary approach to treat chronic pain combining 5 commercially available drugs covering multiple biological pathways, that we call GBM5. As the combination is reduced to 4 or less products, it is necessary to increase the dose of each remaining product substantially to obtain a similar clinical effect, and thus, requiring the use of all 5 commercially available products to provide optimal results. We intend to deliver GBM5 via intranasal route and are in discussions with approved vendors of such devices to take this approach into the clinic. Releve Therapeutics has a solid IP portfolio, a favorable freedom-to-operate opinion from a law office, and No Objection Letters to pursue clinical trials using GBM5. Kind Regards, Omar
Ready to Ask For Funding for your company?
Post a Funding Request